Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CEACAM5 drug discovery. Choose your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CEACAM5 ECD-Fc / His-Tagged Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CEACAM5 Products |
| Gene Delivery | CEACAM5 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for Flow Cytometry validation. |
View CEACAM5 Products |
| Benchmark Ab | Anti-CEACAM5 (Sequence of Cibisatamab/Tusamitamab) Recombinant positive control for comparative assays. |
View CEACAM5 Products |
| Validator | CEACAM5 siRNA Set For knockdown verification to ensure antibody specificity. |
View CEACAM5 Products |
| Related Target A | CEACAM1 Critical homology screening target to prevent off-target toxicity. |
View CEACAM1 Products |
| Related Target B | CEACAM6 Highly homologous family member; essential for cross-reactivity profiling. |
View CEACAM6 Products |
| Related Target C | CEACAM7 Additional CEACAM subfamily member for off-target assessment. |
View CEACAM7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Homology (Off-target binding to CEACAM1/6/7) | CEACAM Homolog Panel proteins available; Sequence Verified, strictly quality-controlled for accurate cross-reactivity screening. |
| Complex Glycosylation Requirements | HEK293 Expressed CEACAM5 ensures native-like folding and correct glycosylation profiles for conformational epitopes. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives in Cell Assays | Validated siRNA included for definitive specificity checks. |
| Internalization Efficiency (ADC Payload Delivery) | Lentivirus Stable Cell Lines: GPI-anchored full-length CEA on HEK293 cells for flow cytometry-based internalization assays. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cynomolgus CEACAM5 ortholog proteins available with sequence-verified ECDs. |
| Shedding vs Membrane-Bound Discrimination | Full-length Lentivirus vs ECD-Fc Protein pair for comparative binding studies. |
Live CEACAM5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CEACAM5 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and T-cell engaging bispecifics. As first-generation therapies navigate clinical evaluation in colorectal, gastric, and non-small cell lung cancers, the next wave of R&D is targeting highly specific epitope binding to overcome the "antigen sink" effect of soluble CEA and strictly avoiding cross-reactivity with other CEACAM family members to improve safety profiles. Additionally, novel modalities like radioimmunoconjugates are being explored to leverage the high tumor-to-background ratio of CEACAM5 imaging.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Sanofi, Daiichi Sankyo, Gilead/Immunomedics | NSCLC, Colorectal Cancer | Internalization Assay (Need high-purity ECD-Fc for accurate binding/uptake studies; Cell lines for internalization) |
| Bispecific (T-Cell Engager) | Roche, Regeneron, Amgen | Solid Tumors, GI Malignancies | Specificity Validation (Need CEACAM Homolog Panels to avoid CEACAM1/6/7 binding) |
| CAR-T | Various Biotechs, Mayo Clinic | Gastric, Pancreatic, Colorectal Cancer | Cell Line Construction (Need Lentivirus for target-expressing target cells) |
| Radioimmunotherapy | RadioMedix | Metastatic CRC | Stable Antigen for repeated binding studies (Endotoxin-controlled) |